Utidelone Capsule Plus Capecitabine (CAP) for Metastatic Breast Cancer
Status:
RECRUITING
Trial end date:
2025-12-05
Target enrollment:
Participant gender:
Summary
This study aims to investigate the efficacy and safety of utidelone capsule plus Capecitabine in the treatment of advanced breast cancer , and thus provides a new systemic treatment strategy for those patients.
This study was a single-arm, phase II study of patients with recurrent or metastatic HER2-negative breast cancer who had previously received chemotherapy regimens containing taxanes and/or anthracyclines were treated with a combination of utidelone capsules and capecitabine. The main objective was to explore the efficacy and safety of the combined regimen.